L
Lila Adnane
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 9
Citations - 6215
Lila Adnane is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Receptor tyrosine kinase & Kinase. The author has an hindex of 5, co-authored 9 publications receiving 5693 citations.
Papers
More filters
Journal ArticleDOI
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott Wilhelm,Christopher A. Carter,LiYa Tang,Dean Wilkie,Angela McNabola,Hong Rong,Charles Chen,Xiaomei Zhang,Patrick Vincent,Mark McHugh,Yichen Cao,Jaleel Shujath,Susan Gawlak,Deepa Eveleigh,Bruce Rowley,Li Liu,Lila Adnane,Mark Lynch,Daniel Auclair,Ian W. Taylor,Rich Gedrich,Andrei Voznesensky,Bernd Riedl,Leonard Post,Gideon Bollag,Pamela A. Trail +25 more
TL;DR: Data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
Journal ArticleDOI
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
TL;DR: This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclinical setting.
Journal ArticleDOI
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott Wilhelm,Jacques Dumas,Lila Adnane,Mark Lynch,Christopher A. Carter,Gunnar Schütz,Karl-Heinz Thierauch,Dieter Zopf +7 more
TL;DR: Data demonstrate that regorafenib is a well‐tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.
Journal ArticleDOI
Recent Advances in the Research and Development of RAF Kinase Inhibitors
TL;DR: Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are outlined.
Journal ArticleDOI
Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
Heike Petrul,Christoph Schatz,Charlotte Christine Kopitz,Lila Adnane,Timothy Mccabe,Pamela A. Trail,Sha Ha,Yong S. Chang,Andrei Voznesensky,Gerald Ranges,Paul Tamburini +10 more
TL;DR: In preclinical human xenograft models in mice representing several tumor indications, BAY 79-4620 showed potent antitumor efficacy and in some models showed partial and complete tumor shrinkage even following a single dose.